drugset
drugset / Trial / NCT05503888

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

NCT05503888 ↗

Phase 1/2 Not yet recruiting 160 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
RandomizedFactorialOpen-labelTreatment

Summary

To evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of Almonertinib combined with SHR-1701 in relapsed or advanced NSCLC To evaluate the efficacy of Almonertinib combined with SHR-1701 in the first-line treatment of relapsed or advanced NSCLC

Timeline

Start
2022-10-01
Primary completion
2027-07-30
Completion
2027-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Almonertinib Small molecule — Oral
Subject Retlirafusp alfa Protein / enzyme biologic — Intravenous

Indications

non-small cell lung carcinoma